GlassScriptPhysician profile
Chee H Woo
NPI 1992703805
$3,435.44
in general payments reported to CMS, 2019-2025
43 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985 · 2020: $302 · 2021: $410 · 2022: $545 · 2023: $588 · 2024: $380 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $521.88 | 2019-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $242.80 | 2019-2023 | Ztlido |
| Lilly USA, LLC | $180.21 | 2019-2024 | Emgality, Reyvow |
| Electronic Waveform Lab, INC. | $172.97 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $162.10 | 2019-2021 | |
| Medtronic USA, INC. | $155.94 | 2019 | |
| Daiichi Sankyo INC. | $155.89 | 2019 | |
| Pfizer INC. | $151.46 | 2019-2025 | |
| Abbott Laboratories | $141.94 | 2023-2025 | Penta, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.64 | 2019-2024 | Relistor |
| Relievant Medsystems, INC. | $102.15 | 2022 | |
| Nevro Corp. | $100.93 | 2019-2024 | Senza |
| Astrazeneca Pharmaceuticals LP | $100.14 | 2019-2024 | Wainua |
| Abbvie INC. | $99.35 | 2021-2025 | |
| Ibsa Pharma INC. | $88.45 | 2021-2024 | Tirosint, Licart, Licart |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chee Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.